Advertisement
Journal Home
Search for

Volume 45, Issue 12, Pages 1006-1010 (December 2009)


View previous. 12 of 25 View next.

Saliva as a tool for oral cancer diagnosis and prognosis

Rafael M. NaglerCorresponding Author Informationemail address

Received 17 April 2009; received in revised form 6 July 2009; accepted 6 July 2009. published online 15 October 2009.

Summary 

Saliva testing, a non-invasive alternative to serum testing, may be an effective modality for diagnosis and for prognosis prediction of oral cancer, as well as for monitoring post therapy status, by measuring specific salivary macromolecules, examining proteomic or genomic targets such as enzymes, cytokines, growth factors, metalloproteinases, endothelin, telomerase, cytokeratines, mRNA’s and DNA transcripts. Salivary analysis has been shown to be a useful diagnostic tool also for distant malignancies such as breast cancer. In recent years, significant alterations have been demonstrated in the saliva of oral cancer patients in the epithelial tumor markers – Cyfra 21-1, TPS and CA12, various oxidative stress-related salivary parameters as ROS and RNS, biochemical and immunological parameters as IGF and MMP’s and RNA transcripts of IL8, IL-1B, DUSP1, HA3, OAZ1, S100P, and SAT. Collectively these accumulated data are predicted to alter the field of oral cancer diagnosis by employing highly sensitive new tools which will enable both medical professionals and the patients themselves to monitor their saliva for diagnosis and prognosis prediction, as they relate to oral cancer. At this point however, the aim of salivary analysis is mainly for screening which may be helpful in the future.

Department of Oral and Maxillofacial Surgery and Oral Biochemistry Laboratory, Rambam Medical Center and Rappaport Faculty of Medicine, Israel Institute of Technology-Technion, Haifa 31096, Israel

Corresponding Author InformationTel.: +972 4 644 2003; fax: +972 4 654 1295.

PII: S1368-8375(09)00849-5

doi:10.1016/j.oraloncology.2009.07.005


View previous. 12 of 25 View next.

Advertisement